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The Primary Immune Deﬁciency Treatment Consortium
(PIDTC) conducted a retrospective study of 240 SCID pa-
tients transplanted at 25 consortium centers from 2000-
2009. Patients with a diagnosis of typical SCID, as deﬁned
by recently published PIDTC consensus criteria, who un-
derwent allogeneic HCT were included after central review.
Leaky SCID and Omenn syndrome were excluded. Donors
included matched sibling (MSD), T-cell depleted (TCD)
mismatched related (MMRD), and unmodiﬁed other
related/unrelated donors (OD). Cell sources included bone
marrow (BM), peripheral blood (PB) and umbilical cord
blood (UCB) (See Table). The vast majority of MSD and TCD
MMRD HCT were performed without conditioning and the
rest were divided between those receiving immunosup-
pression (IS, no busulfan, thiotepa or melphalan), reduced
intensity (RIC, containing alkylating agents equivalent to
<12 mg/kg busulfan) and myeloablative conditioning (MAC,
equivalent to ¼ or >12 mg/kg busulfan). The overall 5-year
survival (OS) rate was 74% (178/240). Multivariate analysis
of OS revealed superior outcomes for MSD when compared
to TCD MMRD or unmodiﬁed OD grafts (Fig. 1A). However,
irrespective of the type of transplant administered, patients
age <3.5 months and patients of any age who were free of
infection at HCT, all had excellent OS, similar to MSD (OS
88-100%) (Fig. 1B-E). Thus, freedom from infection at HCT
had a central role in outcomes of non-MSD HCT for SCID.
Conditioning with RIC/MAC did not affect survival (Fig. 1F).
RIC/MAC also did not inﬂuence donor T cell engraftment in
MSD recipients, who had the lowest rate of 2nd transplant
(6.3%) despite lack of conditioning, nor in non-MSD re-
cipients (2nd transplant none/IS 23% vs. RIC/MAC 16%).
However, while 92% of all patients tested had normal T cell
responses to mitogens, the likelihood of T cell recoveryTotal
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Figure 1.(CD3+ >1000/ul) was signiﬁcantly enhanced by RIC/MAC.
Donor type and genetic subtype of SCID also inﬂuenced T-
cell recovery following non-MSD HCT. Humoral immunity
was consistently achieved post MSD HCT despite lack of
conditioning; for patients who received non-MSD HCT, IVIG
independence was much more likely in those who received
RIC/MAC (84.6% vs. 28.2%, p<0.001). Our study indicates
that all transplant types analyzed can result in excellent
survival when applied to infants with SCID identiﬁed early,
before onset of infections, underscoring the critical impor-
tance of universal newborn screening for SCID. While
the use of RIC/MAC in non-MSD recipients led to im-
provements in some aspects of immune recovery, the risks
of adverse effects on development, neurocognition, and
fertility remain a concern, and illustrate the need for less
toxic regimens.5
HLA-Mismatch Is Associated with Worse Outcomes after
Myeloablative Conditioning and Unrelated Donor
Hematopoietic Cell Transplantation: A Cibmtr Analysis
Joseph Pidala 1, Stephanie J. Lee 2, Stephen R. Spellman 3,
Hailin Wang 4, Kwang Woo Ahn 5, Mahmoud D. Aljurf 6,
Medhat Askar 7, Jason Dehn 8, Marcelo A. Fernandez Viña 9,
Alois Gratwohl 10, Vikas Gupta 11, Rabi Hanna 7,
Carolyn K. Hurley 12, Yoshihiro Inamoto 2, Adetola A. Kassim 13,
Taiga Nishihori 14, Machteld Oudshoorn 15, Efﬁe W. Petersdorf 2,
Vinod K. Prasad 16, Wael Saber 4, Kirk R. Schultz 17,
William A. Wood 18, Jan Storek 19, Ann E. Woolfrey 2,
Claudio Anasetti 14. 1H. Lee Mofﬁtt Cancer Center and Research
Institute, Tampa, FL; 2Fred Hutchinson Cancer Research Center,
Seattle, WA; 3Immunobiology and Observational Research,
Center for International Blood and Marrow Transplant
Research, Minneapolis, MN; 4CIBMTR, Medical College of
Wisconsin, Milwaukee, WI; 5Division of Biostatistics, Medical
College of Wisconsin, Milwaukee, WI; 6King Faisal Specialist
Hospital and Research Centre, Riyadh, Saudi Arabia; 7Cleveland
Clinic, Cleveland, OH; 8National Marrow Donor Program,
Minneapolis, MN; 9Stanford Hospital and Clinics, Stanford, CA;
10Hematology & Stem Cell Transplant Unit, University Hospital
Basel, Basel, Switzerland; 11Allogeneic Blood and Marrow
Transplant Program, Princess Margaret Cancer Center,
University of Toronto, Toronto, ON, Canada; 12Georgetown
University Hospital, Washington, DC; 13Vanderbilt University
Medical Center, Nashville, TN; 14Blood and Marrow
Transplantation, H. Lee Mofﬁtt Cancer Center and Research
Institute, Tampa, FL; 15Europdonor Foundation, Leiden
University Medical Centre, Leiden, Netherlands; 16Pediatric
BMT Program, Duke University Medical Center, Durham, NC;
17British Columbia’s Children’s Hospital, Vancouver, BC,
Canada; 18University of North Carolina Hospitals, Chapel Hill,
NC; 19Tom Baker Cancer Centre/Foothills Hospital, Calgary, AB,
Canada
Background: Previous studies have demonstrated the
adverse impact of HLA mismatch on the outcome of mye-
loablative conditioning and unrelated donor allogeneic he-
matopoietic cell transplantation (HCT). These have had
limited power in certain sub-groups, and do not reﬂect
changes in HCT utilization and technology.
Methods: Included were adult and pediatric patients who
had undergone ﬁrst myeloablative unrelated bone marrow
or peripheral blood HCT for AML, ALL, CML, or MDS between
1999 and 2011. Patient and donor had high resolution typing
for HLA-A, B, C, DRB1, DQB1, and DPB1. Study outcomes
included overall survival (OS), disease-free survival (DFS),
treatment-related mortality (TRM), malignancy relapse,
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primary analysis tested the impact of mismatch at HLA-A, B,
C and DRB1. Secondary analyses examined HLA locus-speciﬁc
effects, allele vs. antigen mismatch, and the impact of DPB1
and DQB1 mismatch. Additional patient, disease, and HCT
variables were considered in multivariate analyses. A p value
< 0.01 was considered signiﬁcant.
Results: Of the study population (n¼8,003), cases were 8/8
(n¼5,449), 7/8 (n¼2,071), or 6/8 (n¼483) matched. Median
follow up for surviving patients was 49 (3-151) months. The
study population was 88% Caucasian, 67% KPS 90-100, 77%
acute leukemia and only 14% CML, 56% peripheral blood, and
43% non-TBI myeloablative conditioning. Of the total, 20%
were from 1999-2002, 32% 2003-2006, and 49% from 2007-
2011. In the primary analysis, HLA mismatch (6-7/8)
conferred signiﬁcantly increased risk for grade II-IV and III-IV
acute GVHD, chronic GVHD, and TRM, and worsened DFS and
OS compared to HLA matched cases (8/8). Malignancy
relapse was not affected by HLA mismatch at A, B, C, or DRB1.
The 6/8 cases had signiﬁcantly worse TRM than 7/8 cases.
The adverse impact of HLA mismatch on OS was greatest
among those with early or intermediate stage disease. Single
mismatch at HLA-A, B, and C increased the risk for acute
GVHD, TRM, and worsened OS. While single antigen
mismatch at HLA-B increased risk for grade II-IV acute GVHD
over single allele mismatch at eB, no other differences were
detected between allele or antigen mismatch. Among 8/8
matched cases, DPB1 mismatch was associated with
increased grade II-IV and III-IV acute GVHD and decreased
relapse, and DQB1 mismatch was associated with increased
grade II-IV acute GVHD; these effects were not observed
among 7/8 cases. DPB1 and DQB1 mismatch among 7/8 or 8/
8 cases had no effect on OS or DFS.
Conclusions: Despite improvements in survival after unre-
lated donor HCT over time, donor-recipient HLA disparity
remains a major source of GVHD and mortality.6
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Adoptive transfer of T cells with a CD19-speciﬁc chimeric an-
tigen receptor (CAR) to treat B-cell malignancies shows
remarkable clinical efﬁcacy.However, long-termpersistenceof
T cells targeting CD19, a pan-B cell marker, causes depletion
of normal B cells and consequent severe hypogammaglobu-
linemia. In order to target B-cellmalignanciesmore selectively,
we have taken advantage of the clonal restriction of mature
B-cell malignancies, which express either a k or a l-light
immunoglobulin chain.Wegenerated aCAR speciﬁc for k-light
chain (CAR.k) to selectively targetk+ lymphoma/leukemia cells,
while sparing the normal B cells expressing the non-targeted
l-light chain, thus minimizing the impairment of humoral
immunity. After validation in preclinical experiments, we
designed a phase I clinical trial in which patients with re-
fractory/relapsed k+ NHL/CLL are infused with autologous T
cells expressing a CAR.k that includes a CD28 costimulatory
domain. The protocol also allows for the inclusion of patients
with multiple myeloma (MM) with the aim of targeting pu-
tativemyeloma initiating cells. Threedose levels (DL) are being
assessed: 0.2 (DL1), 1 (DL2) and 2 (DL3) 108 T cells/m2.
Tcellsweregenerated for 13patients byactivating autologous
PBMC with OKT3 (n¼5) or CD3/CD28 monoclonal antibodies
(n¼8). In 2 patients with >95% circulating CLL cells, CD3
positive selection was performed using CliniMACS. After
transduction, T cells (1.21070.5107) were expanded ex
vivo for 184 days in the presence of IL-2 to reach sufﬁcient
numbers for dose escalation. CARexpressionwas 81%13%by
ﬂow cytometry. Products were composed predominantly of
CD8+ cells (78%10%). CAR+ T cells speciﬁcally targeted k+
tumors (speciﬁc lysis by 51Cr release 79%10%, 20:1 E:T ratio)
but not ke tumors (11%7%) or theNK-sensitive cell line K562
(26%13%). Ten patients were treated so far: 2 on DL1, 3 on
DL2 and 5 onDL3. Any other treatmentswere discontinued at
least 4 weeks prior to T-cell infusion and patients with ALC
>500 received 12.5 mg/kg cyclophosphamide 4 days before
infusion. Infusions werewell toleratedwithout side effects. A
CAR.k-speciﬁc Q-PCR assay showed that molecular signals
peaked 1-2 weeks post infusion and remained detectable for
at least 6 weeks and up to 9 months in 1 patient. Of the 5
patients with relapsed NHL, 2 entered complete remission
(after 2 and 3 infusions at DL1 and DL3, respectively), 1 had a
partial response and2progressed; 3/3 patientswithMMhave
had stable disease for 2,11 and 17months, associatedwith up
to 38% reduction in their paraprotein; and 2/2 patients with
CLL progressed before or shortly after the 6 week evaluation.
In conclusion, our data indicate that infusion of CAR.k+ T cells
is safe at every DL and can be effective in patients with k+
lymphoma.
